MedPath

Los Angeles Shigellosis Outbreak Caused by Mutation

A mutation in the Shigella sonnei bacteria has led to an extensively drug-resistant (XDR) Shigellosis outbreak in Los Angeles, with California reporting 4,365 of the 20,621 cases nationwide in 2024. The mutation makes the bacteria resistant to cephalosporins, a class of antibiotics, highlighting the urgent need for improved detection and management strategies.

In 2024, California led the United States in extensively drug-resistant (XDR) Shigellosis outbreaks, with 4,365 cases reported out of a national total of 20,621. A Brief Report published by AJIC on December 9, 2024, detailed a mutation in the Shigella sonnei bacteria, making it resistant to five classes of antibiotics commonly used to treat such infections, including cephalosporins.
This XDR Shigella strain is unique to Los Angeles County and underscores the rapid spread of drug-resistant Shigella in the U.S. Since its first detection in California in 2017, the prevalence of XDR Shigella has risen significantly, with 12% of Shigella isolates reported as XDR from January through May 2024. Shigella sonnei isolates accounted for 78% of cases.
The U.S. CDC estimates that Shigellosis is the third most common bacterial enteric disease, with 20,621 cases confirmed by the end of 2024. In 2023, the CDC reported 17,176 cases nationwide.
Efforts to combat this outbreak include the development of the Shigella4V (S4V) vaccine by Valneva SE and LimmaTech Biologics AG, which entered a Phase 2b clinical trial on November 13, 2024. The U.S. FDA has granted Shigella4V Fast Track designation, indicating the urgency of addressing this public health challenge.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

GSK's Shingrix Prefilled Syringe Under Review by FDA and EMA for Shingles Prevention

The FDA and EMA are reviewing GSK's application for a Shingrix prefilled syringe, potentially streamlining vaccine administration.
The new syringe formulation aims to simplify the vaccination process by removing the need for reconstitution.

FDA Breakthrough: First mRNA Vaccine Approved for Epstein-Barr Virus-Related Cancer

The FDA has approved WGc-043, marking a historic milestone as the first mRNA vaccine developed for treating Epstein-Barr virus-related cancers. This groundbreaking development represents a significant advancement in oncology treatment, offering new therapeutic options for patients with advanced EBV-related malignancies.

FDA Approves Bavarian Nordic's Vimkunya, First Chikungunya Vaccine for Adolescents

The FDA has approved Vimkunya, a chikungunya vaccine developed by Bavarian Nordic, for individuals aged 12 and older.
Vimkunya is the first virus-like particle (VLP) single-dose chikungunya vaccine approved in the U.S., offering a new preventative option.

Valneva and LimmaTech Initiate Phase 2b Human Challenge Study for Shigella Vaccine Candidate S4V2

Valneva and LimmaTech have commenced a Phase 2b controlled human infection model (CHIM) study of their Shigella vaccine candidate, S4V2.
The study will evaluate the safety and preliminary efficacy of S4V2 in approximately 120 healthy adults challenged with _Shigella sonnei_.

Antengene's Selinexor Shows Promise in Multiple Myeloma and Lymphoma Studies

Antengene will present Phase III trial results of weekly selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in Chinese patients with relapsed/refractory multiple myeloma (RRMM).
Preliminary results from a Phase I/II study of selinexor combined with tislelizumab in relapsed/refractory extranodal NK/T-cell lymphoma (R/R ENKTL) will also be presented.

Antengene to Present Selinexor Data from Phase III Multiple Myeloma and Phase I/II Lymphoma Studies at ASH 2024

Antengene will present Phase III results of weekly selinexor, bortezomib, and dexamethasone (SVd) versus bortezomib and dexamethasone (Vd) in Chinese patients with relapsed/refractory multiple myeloma.
Preliminary results from a Phase I/II study of selinexor combined with tislelizumab in relapsed/refractory extranodal NK/T-cell lymphoma will also be presented.

FDA Approves Alvotech and Teva's SELARSDI (ustekinumab-aekn) for Crohn's Disease and Ulcerative Colitis

The FDA has approved a new intravenous infusion presentation of SELARSDI, expanding its label to include Crohn’s disease and ulcerative colitis.
This approval aligns SELARSDI's indications more closely with its reference product, Stelara (ustekinumab), enhancing its market potential.

Valneva and LimmaTech Receive FDA Fast Track Designation for Shigella Vaccine Candidate

Valneva and LimmaTech's Shigella4V (S4V), a tetravalent bioconjugate vaccine candidate, has received FDA Fast Track designation, aimed at expediting the development of treatments for serious conditions.
Shigellosis, caused by Shigella bacteria, affects up to 165 million people annually, resulting in approximately 600,000 deaths, particularly impacting children in low- and middle-income countries.

Edelife XLHED Clinical Trial Expands to Cedars-Sinai in Los Angeles

The Edelife clinical trial, evaluating ER-004 for X-linked hypohidrotic ectodermal dysplasia (XLHED), has opened a new site at Cedars-Sinai Medical Center in Los Angeles.
Cedars-Sinai is the second U.S. location for the trial, aiming to enroll 15-20 babies and offering to cover all associated expenses for participating families.

Axicabtagene Ciloleucel Approved for Second-Line LBCL Treatment

Axicabtagene ciloleucel (axi-cel) has received FDA approval for adult patients with large B-cell lymphoma (LBCL) that is refractory to first-line chemoimmunotherapy or relapses within 12 months.
The approval was based on the ZUMA-7 trial, which demonstrated a significant improvement in event-free survival compared to standard therapy involving chemoimmunotherapy and stem cell transplantation.

Reference News

[1]
Los Angles Shigellosis Outbreak Caused by Mutation - Vax-Before-Travel
precisionvaccinations.com · Jan 5, 2025

In 2024, California led in XDR Shigellosis outbreaks with 4,365 of 20,621 U.S. cases. A mutation in Shigella sonnei, res...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy